Clinical Relevance and Management of Drug‐Related QT Interval Prolongation
- 1 July 2003
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 23 (7) , 881-908
- https://doi.org/10.1592/phco.23.7.881.32730
Abstract
Much attention recently has focused on drugs that prolong the QT interval, potentially leading to fatal cardiac dysrhythmias (e.g., torsade de pointes). We provide a detailed review of the published evidence that supports or does not support an association between drugs and their risk of QT prolongation. The mechanism of drug‐induced QT prolongation is reviewed briefly, followed by an extensive evaluation of drugs associated with QT prolongation, torsade de pointes, or both. Drugs associated with QT prolongation are identified as having definite, probable, or proposed associations. The role of the clinician in the prevention and management of QT prolongation, drug‐drug interactions that may occur with agents known to affect the QT interval, and the impact of this adverse effect on the regulatory process are addressed.Keywords
This publication has 195 references indexed in Scilit:
- Antiarrhythmic AgentsDrug Safety, 2000
- MoxifloxacinDrugs, 2000
- Long QT syndromes and torsade de pointesThe Lancet, 1999
- Second-Generation AntihistaminesDrugs, 1999
- Torsade de pointes after inhaled pentamidineAnnals of Emergency Medicine, 1992
- Cardiotoxic effects of astemizole overdose in childrenThe Journal of Pediatrics, 1992
- Torsades de pointes occurring in association with terfenadine useJAMA, 1990
- Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial InfarctionNew England Journal of Medicine, 1989
- Probucol in long-term treatment of hypercholesterolemiaGeneral Pharmacology: The Vascular System, 1988
- Arsenic-Induced Atypical Ventricular TachycardiaNew England Journal of Medicine, 1980